The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.

Dyer, Martin J.S.; Hutchinson, Claire V.; Rule, Simon; Shah, Nimish; Salles, Gilles; Karlin, Lionel; Morschhauser, Franck; Terriou, Louis; Fegan, Christopher; Davison, Andrew S.; Cartron, Guillaume; Saunders, Andrew; Honda, Hideyuki; Sharpe, John C.; Yoshizawa, Toshio; Yasuhiro, Tomoko; Kawabata, Kazuhito; Awata, Hiroshi; Birkett, Joseph

doi:10.1200/jco.2014.32.15_suppl.8553

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first-in-human phase I study of ONO/GS-4059 was ongoing in relapsed/refractory B-cell malignancies (NCT01659255) [ 63 , 73 – 75 ]. In the last update, 90 patients were evaluable for the efficacy and safety.…”

Section: Ono/gs-4059 In Clinical Developmentmentioning

confidence: 99%

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

Zhang

Liu

2016

Oncotarget

View full text Add to dashboard Cite

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibrutinib. More selective and potent BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being investigated. This review summarized the preclinical research and clinical data of ONO/GS-4059.

show abstract

Section: Ono/gs-4059 In Clinical Developmentmentioning

confidence: 99%

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

Zhang

Liu

2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…With ONO-4059, 13 patients with relapsed non-GCB DLBCL have been treated with doses ranging from 160–480 mg daily, and 6 of 8 evaluable patients have achieved a PR. 16 …”

Section: Diffuse Large B-cell Lymphomamentioning

confidence: 99%

B-cell receptor pathway modulators in NHL

Blum

2015

Hematology

View full text Add to dashboard Cite

With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor, idelalisib, in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), a number of new agents targeting the B-cell receptor (BCR) pathway are in clinical development. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. This review will summarize the current data with the use of single agent and combination therapy with BCR inhibitors in NHL. In addition, commonly encountered as well as serious toxicities and hypothesized resistance mechanisms will be discussed. Lastly, this review will examine the future of these agents and opportunities to maneuver them into the front-line setting in selected NHL subtypes.

show abstract

Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias

Tees

Sokol

2016

American Journal of Therapeutics

View full text Add to dashboard Cite

Novel pharmacotherapeutic agents were recently approved for treatment of low-grade B-cell neoplasms, and many other agents are under investigation. Several agents have demonstrated impressive activity in targeting malignant B-cell processes and specific pathways, all with the potential to expand our ability to effectively treat B-cell malignancies. The inhibitors of several cell regulatory proteins, including Bruton tyrosine kinase (Btk), phosphoinositide 3-kinase (PI3-K), B-cell lymphoma/leukemia-2 (Bcl-2), and histone deacetylases, as well as immunomodulatory agents are a few of the many pharmacotherapeutic agents under study. A comprehensive review and assessment is presented of the current pharmacotherapies under investigation targeting B-cell lymphomas and leukemias.

show abstract

The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.

Cited by 5 publications

References 0 publications

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

B-cell receptor pathway modulators in NHL

Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias

Contact Info

Product

Resources

About